Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:30 PM
Ignite Modification Date:
2025-12-24 @ 5:30 PM
NCT ID:
NCT01113268
Eligibility Criteria:
Inclusion Criteria:
\*Selection criteria
Any patient hospitalised in the CCU of the participating centers:
* with a diagnosis of a first MI
* with ST segment elevation and/or Q wave at admission
* with troponin elevation
* seen within the first 24 hours after symptom onset
* aged between 18 and 80 years is selected.
* consent emergency clause: His/her informed consent is obtained and he/she signs the consent form or However, if a member of the patients' family is present, his/her consent must be obtained or no consent
\*Inclusion
* The first transthoracic echocardiography is performed at day 4±2 in all patients selected.
* In the presence of at least 3 akinetic LV segments at the transthoracic echocardiography, the patient is included.
Exclusion Criteria:
\*Non-selection criteria:
* Informed consent not obtained.
* Patients with diagnosis of previous MI, hypertrophic or dilated cardiomyopathy, significant valvular heart disease, chronic atrial fibrillation, or pace maker or any permanently implanted device susceptible to interfere with LV remodelling.
* Patients with preexisting heart failure.
* Patients having undergone previous cardiac surgery.
* Patients having received chemotherapy susceptible to induce LV remodeling (anthracyclines).
* Patients with an associated short-time life-threatening disease.
* Patients with poor echogenicity.
* Patients without health insurance.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT01113268
Study Brief:
Protocol Section:
NCT01113268